Leap Therapeutics Reports First Quarter 2017 Financial Results
CAMBRIDGE, Mass., May 12, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2017. The company also announced that an investigator-sponsored clinical trial of DKN-01 will be conducted in patients with advanced hepatocellular carcinoma (HCC) at the University Medical Center of the Johannes Gutenberg-University Mainz in Germany.
“The hepatocellular carcinoma study is an important element of our plan to test DKN-01 in genetically-defined cancer populations,” commented Christopher K. Mirabelli, Ph.D, Chief Executive Officer of Leap Therapeutics. “We continue to pursue an aggressive clinical development plan for both of our programs and are highly encouraged by the positive clinical data we presented this quarter.”
“The hepatocellular carcinoma study is an important element of our plan to test DKN-01 in genetically-defined cancer populations,” commented Christopher K. Mirabelli, Ph.D, Chief Executive Officer of Leap Therapeutics. “We continue to pursue an aggressive clinical development plan for both of our programs and are highly encouraged by the positive clinical data we presented this quarter.”